TISSIUM: Funding, Investors & Team (Sep 2026)
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues, and deliver on-demand wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC, and CapDecisif Management.
TISSIUM has raised $88.0M across 2 funding rounds on record, the most recent a Series D of $34.0M announced in Jun 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
TISSIUM Company Profile and Key Stats
Latest funding round on record: Jun 2026.
TISSIUM Funding Rounds
TISSIUM raised $54.0M in a Series D announced in May 2023.
3.1 years later, a Series D of $34.0M was announced in Jun 2026.
TISSIUM Founders and Leadership Team
Contact details for the TISSIUM team: 1 of 1 has an email address on file.
Start 14-day free trial →TISSIUM Funding Compared to Other Biotechnology Startups
TISSIUM's latest round of $34.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like TISSIUM in Biotechnology and Paris
Companies Similar to TISSIUM
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Kahimmune Therapeutics is a cutting-edge biotech startup that is repurposing the cancer immunopeptidome to…
TISSIUM Funding FAQs
What does TISSIUM do?
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues, and deliver on-demand wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC, and CapDecisif Management.
How much funding has TISSIUM raised?
TISSIUM has raised $88.0M across 2 rounds on record. The most recent is a Series D of $34.0M announced in Jun 2026.
When did TISSIUM last raise funding?
TISSIUM's most recent funding round on record is a Series D of $34.0M, announced in Jun 2026.
Who is the CEO of TISSIUM?
Christophe Bancel is listed as CEO at TISSIUM.
Where is TISSIUM headquartered?
TISSIUM is based in Paris, Ile-De-France, France.
How many employees does TISSIUM have?
TISSIUM is in the 51-100 employee band.
How does TISSIUM's funding compare to other Biotechnology startups?
TISSIUM's latest round of $34.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's TISSIUM Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for TISSIUM is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.